Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi最新文献

{"title":"[Hypoprothrombinemia-lupus anticoagulant syndrome: a case report and literature review].","authors":"P J Wang, W Liu, T Sun, Y H Wang, R C Yang, L Zhang, F Xue","doi":"10.3760/cma.j.cn121090-20241129-00496","DOIUrl":"10.3760/cma.j.cn121090-20241129-00496","url":null,"abstract":"<p><p>The Hypoprothrombinemia-Lupus Anticoagulant Syndrome (HLAS) is a rare coagulation disorder, typically presenting with bleeding manifestations. It is characterized by decreased prothrombin activity and the presence of lupus anticoagulant, but laboratory findings are complex, which can delay diagnosis and treatment. This report describes the diagnosis and management of a HLAS patient who was an 11-year-old girl with recurrent bleeding. Coagulation tests revealed prolonged APTT and PT, decreased prothrombin activity, and immediate inhibitory antibodies in the APTT correction test. Lupus anticoagulant, antiphospholipid antibodies, anti-β(2)-glycoprotein 1 antibodies, and phosphatidylserine/prothrombin (aPS/PT) antibodies were positive, leading to a diagnosis of Hypoprothrombinemia-Lupus Anticoagulant Syndrome. The patient was also diagnosed with systemic lupus erythematosus. Following corticosteroid therapy, prothrombin activity returned to normal.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"45 S1","pages":"89-91"},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Comparison of the efficacy and safety between high-dose intravenous iron and oral iron in treating iron deficiency anemia: a multicenter, prospective, open-label, randomized controlled study].","authors":"Q Zhang, H Wang, Y M Zhang, X L Li, Y Y Shen, N Wei, K Zou, W X Su, H P Dai, D P Wu, L M Liu","doi":"10.3760/cma.j.cn121090-20240424-00161","DOIUrl":"10.3760/cma.j.cn121090-20240424-00161","url":null,"abstract":"<p><p><b>Objective:</b> This study aimed to compare the efficacy and safety between high-dose intravenous iron and oral iron in treating iron deficiency anemia (IDA) . <b>Methods:</b> This prospective randomized controlled study (1∶1) enrolled 338 patients with IDA at The First Affiliated Hospital of Soochow University, Suzhou Hongci Hematology Hospital, and Huai'an Second People's Hospital from June 1, 2022, to January 19, 2024. Of all the patients, 169 received high-dose intravenous iron therapy and 169 received oral iron treatment for 12 weeks of observation. Focus on the hemoglobin (HGB) change from baseline to week 4, secondary focus was on the HGB and iron metabolism parameters (serum iron [SI], transferrin saturation [TSAT], total iron binding force [TIBC], serum ferritin [SF]), and changes in the fatigue score, efficacy, and treatment-related adverse effects were monitored throughout in the two treatment groups. <b>Results:</b> The HGB levels were improved in both treatments, but the HGB improved faster in the intravenous group compared with the oral group. HGB increased from (76.8±15.0) g/L to (118.0±13.3) g/L in the intravenous group and from (77.9±11.6) g/L to (104.3±15.0) g/L in the oral group after 4 weeks of treatment. The increase from baseline in the intravenous group (40.7±17.3) g/L was significantly higher than that in the oral group (27.2±17.5) g/L (<i>P</i><0.001). The intravenous group demonstrated a more significant early effect than the oral group in terms of iron metabolism parameter improvement. SI, TSAT, TBIC, and SF increased better from baseline at 4 weeks in the intravenous group than in the oral group (<i>P</i><0.001). Additionally, the intravenous group exhibited better fatigue scores for early improvement than the oral group (<i>P</i><0.001). The incidence of total adverse effects was similar in the intravenous group as compared to the oral group (3.5% [6/169] <i>vs</i> 5.9% [10/169], <i>P</i>=0.442) . <b>Conclusion:</b> High doses of intravenous iron quickly boost HGB early, causing rapid improvement in SI, TSAT, TBIC, SF, and patient fatigue scores. The patient was well tolerated.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"45 12","pages":"1113-1118"},"PeriodicalIF":0.0,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143024834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Advances in the genetics of venous thromboembolic disease].","authors":"Y Q Xia, L Tang, Y Hu","doi":"10.3760/cma.j.cn121090-20240327-00117","DOIUrl":"10.3760/cma.j.cn121090-20240327-00117","url":null,"abstract":"<p><p>Venous thromboembolism (VTE) is clinically manifested as deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE is the third most prevalent vascular disease after coronary artery and cerebrovascular diseases. VTE is a multifactorial disease caused by the interaction of genetic and acquired risk factors. Genetic heritability is estimated to be 40%-60% based on studies of families, twins, and siblings. The accumulation of information linking genetic variations to VTE risk has rapidly expanded with the continuous advancement of sequencing technology. Currently, mutations in key genes of the coagulation system, anticoagulation system, and fibrinolysis system are constantly being updated, and the functional mechanisms of new genes are receiving gaining attention. This review summarizes the research progress and prospects of key genetic variations associated with venous thromboembolism.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"45 12","pages":"1144-1147"},"PeriodicalIF":0.0,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143575776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical characteristics and prognosis analysis in patients with bone marrow invasive follicular lymphoma].","authors":"R Lyu, W J Xiong, T Y Wang, Y T Yan, Q Wang, Y Yu, W Liu, W Y Huang, G An, Y Xu, D H Zou, L G Qiu, S H Yi","doi":"10.3760/cma.j.cn121090-20240613-00222","DOIUrl":"10.3760/cma.j.cn121090-20240613-00222","url":null,"abstract":"<p><p><b>Objective:</b> This study aimed to summarize the clinical characteristics and prognosis of patients with bone marrow invasive follicular lymphoma (FL) and discuss the treatment modalities. <b>Methods:</b> This study included 183 consecutive patients with FL accompanied by bone marrow invasion and receiving regular treatment at the Hospital of Hematology, Chinese Academy of Medical Sciences, from January 2013 to December 2022. Clinical data were retrospectively collected and analyzed, and single and multifactorial analyses of survival prognosis were conducted with the Kaplan-Meier method and Cox regression model. <b>Results:</b> The median age was 48 (range: 19 - 78) years, and the male-to-female ratio was 0.9∶1. All of the patients had bone marrow invasion, 27.8% had increased lactate dehydrogenase levels, 42.1% had lymphocyte counts of >5×10(9)/L, 18.4% had abnormal chromosomal karyotypes, and 48.6% had Ki-67 index of ≥30% in lymphoid tissue. Comparison of different subgroups: lymphocyte counts of >5×10(9)/L, number of lymph nodes of ≥5 involved, and proportion of bone marrow chromosomal abnormalities occurring were higher in the anthracycline-intensive treatment group than in the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) protocol and the nucleoside analog (including CD20 monoclonal antibody in combination with fludarabine and bendamustine) groups (all <i>P</i><0.05). The complete remission rate was 39.1% in the conventional R-CHOP group, which was lower and statistically significant than that in the intensive treatment group (55.1%) and the nucleoside analog group (62.5%) (<i>P</i>=0.042). The multivariate analysis for survival analysis revealed high risk of FLIPI (<i>HR</i>= 1.910, 95% <i>CI</i> 1.036 - 3.522, <i>P</i>=0.036), chromosomal abnormalities karyotype (<i>HR</i>=2.666, 95% <i>CI</i> 1.333-5.331, <i>P</i>=0.006), and conventional R-CHOP treatment (<i>HR</i>=2.287, 95% <i>CI</i> 1.140-4.591, <i>P</i>=0.020) were the independent adverse prognostic factors affecting progression-free survival (PFS), whereas POD24 was the only independent adverse prognostic factor affecting overall survival (OS) adverse prognostic factor (<i>HR</i>=9.581, 95% <i>CI</i> 3.000 - 30.593, <i>P</i><0.001) . <b>Conclusions:</b> The clinical presentations of patients with bone marrow invasive FL were easy to combine the clinical features, including increased lymphocyte count, chromosomal abnormalities, and Ki-67 index in lymphoid tissues. The FLIPI score, chromosomal abnormal karyotype, and high-lymphoid-tissue Ki-67 index were the poor prognostic factors influencing PFS. R-CHOP therapy demonstrated a poor prognosis in this group of patients.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"45 12","pages":"1085-1090"},"PeriodicalIF":0.0,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143575787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical characteristics and treatment efficacy of newly diagnosed acute leukemia in the plateau].","authors":"Q Y He, A L Lai, A Zhang, L N Wang, X M Chen, S W Qiu, H Wei, J X Wang, G J Zhang","doi":"10.3760/cma.j.cn121090-20240514-00182","DOIUrl":"10.3760/cma.j.cn121090-20240514-00182","url":null,"abstract":"<p><p><b>Objective:</b> This study aimed to retrospectively analyze the clinical characteristics and prognosis of patients with acute leukemia in the plateau. <b>Methods:</b> The clinical information of patients diagnosed with acute leukemia from February 2010 to April 2023 at the People's Hospital of Tibet Autonomous Region was reviewed and collected, including blood cell count, morphology, immunophenotype, cytogenetics, and molecular data. Survival analysis was conducted to analyze the outcome of patients with acute leukemia. <b>Results:</b> This study enrolled 105 patients with acute leukemia, including 24 with acute lymphoblastic leukemia (ALL), 62 with acute myeloid leukemia (AML), and 19 with acute leukemia without baseline data. Of the patients with ALL, 11 underwent bone marrow testing for immunophenotype, all of whom were B-cell lineage. The main FAB subtype of patients with AML was M(2) (25/57), followed by M(3) (12/57), M(5) (6/57), M(4EO) (5/57), M(1) (4/57), M(4) (4/57), and M(0) (1/57). The complete remission rates of patients with ALL, acute promyelocytic leukemia (APL), and AML (non-APL) after one course of induction therapy were 57.1% (8/14), 100% (6/6), and 53.6% (15/28), respectively. The median event-free survival (EFS) and overall survival (OS) for patients with ALL were 2 (95% <i>CI</i> 0-9) and 3 (95% <i>CI</i> 0-9) months, respectively, with a median followup of 37 (95% <i>CI</i> 17-57) months. Patients with APL did not reach median EFS or OS, whereas the median EFS and OS for core binding factor AML (CBF-AML) cases were 10 (95% <i>CI</i> 0-21) months and 13 (95% <i>CI</i> 3-23) months, respectively, and patients with non-CBF-AML had inferior median EFS (2 months, 95% <i>CI</i> 1-3) and OS (2 months, 95% <i>CI</i> 1-3) (<i>P</i><0.01). Patients with ALL treated from 2020 to 2023 demonstrated trends toward better EFS (<i>P</i>=0.16) and OS (<i>P</i>=0.10) than those treated from 2010 to 2019. Similarly, trends toward superior EFS (<i>P</i>=0.27) and OS (<i>P</i>=0.12) were observed in patients with AML treated from 2016 to 2023, in comparison with those treated from 2010 to 2015. <b>Conclusion:</b> Progress in the treatment and prognosis of patients with acute leukemia in the plateau has been observed in recent years, which can be further promoted by precision diagnosis and tailored regimens.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"45 12","pages":"1106-1112"},"PeriodicalIF":0.0,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143575791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Progress in risk stratification and treatment of high-risk smoldering multiple myeloma].","authors":"J Q Zhou, M Hao, G An","doi":"10.3760/cma.j.cn121090-20240416-00144","DOIUrl":"10.3760/cma.j.cn121090-20240416-00144","url":null,"abstract":"<p><p>Smoldering multiple myeloma (SMM) patients are a heterogeneous group with variable prognosis. A subset of SMM patients have a higher risk of progressing to multiple myeloma (MM) within 2 years. The definition of high-risk patients is not consistent among different risk models, and the combination of various biomarkers and new technologies improves the predictive performance of risk models. In clinical research, different risk models are often combined and applied. New drugs for treating MM are gradually being applied in the treatment of high-risk SMM. Single or dual drug therapy prolongs the progression free survival of patients, but most studies have not yet shown an overall survival benefit for patients. Multi drug combination and intensive treatment can achieve deep relief in high-risk SMM, but most of the studies are single arm studies, which are not yet sufficient to prove that multi drug treatment is more effective than lower intensity treatment. Further exploration of treatment plans for high-risk SMM patients is still needed. This article reviews the progress in risk stratification and treatment of high-risk SMM.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"45 12","pages":"1148-1152"},"PeriodicalIF":0.0,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143575819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy and safety of gilteritinib combined with chemotherapy in newly diagnosed FLT3-mutated acute myeloid leukemia].","authors":"Y T Lei, X L Zhao, M Hong, W J Liu, Q Sun, S X Qian, S Wang, Y Zhu","doi":"10.3760/cma.j.cn121090-20240615-00224","DOIUrl":"10.3760/cma.j.cn121090-20240615-00224","url":null,"abstract":"<p><p>This study aimed to assess the efficacy and safety of gilteritinib combined with chemotherapy in treating newly diagnosed FLT3-mutated acute myeloid leukemia (AML). We retrospectively collected clinical data from 16 patients newly diagnosed with FLT3-mutated AML at Jiangsu Province Hospital. Patients received induction therapy with the classic \"3 + 7\" regimen or the VA regimen, and all patients were immediately supplied with gilteritinib after detecting FLT3-ITD/TKD mutations. Of the 16 patients, 12 were male and 4 were female, with a median age of 52.5 years (range: 15-76 years). Additionally, 15 patients had FLT3-ITD mutations and 1 had FLT3-TKD mutation. The complete remission (CR/CRi) rate was 93.8% (15/16) after the first cycle of gilteritinib-based induction therapy, with 13 patients achieving MRD negativity detected with flow cytometry. All patients achieved a CR(MRD-) during the consolidation phase. FLT3 mutation clearance was achieved among all 14 patients who underwent next-generation sequencing (NGS) analysis. The 12-month overall survival and relapse-free survival rates were both 73.9%, respectively, with a median followup of 18 months. Nine (56.2%) patients experienced infectious fever during the induction therapy. Three patients had grade 3 QTc prolongation during consolidation and maintenance therapy. Treatment-related adverse events were generally tolerable.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"45 12","pages":"1129-1133"},"PeriodicalIF":0.0,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886698/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143575799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical analysis of oral mucositis after secondary allogeneic hematopoietic stem cell transplantation in patients with hematological diseases].","authors":"X L Zhu, J Z Wang, H X Fu, T T Han, Z L Xu, X H Zhang, L P Xu, X J Huang, Y Wang","doi":"10.3760/cma.j.cn121090-20240701-00240","DOIUrl":"10.3760/cma.j.cn121090-20240701-00240","url":null,"abstract":"<p><p><b>Objective:</b> This study aimed to investigate the clinical characteristics of oral mucositis (OM) in patients with hematological diseases who received secondary allogeneic hematopoietic stem cell transplantation (allo-HSCT) . <b>Methods:</b> This study retrospectively analyzed data on 58 patients with hematological diseases who underwent secondary allo-HSCT at the Peking University People's Hospital from January 2018 to December 2023. The control group included 116 randomized patients after primary allo-HSCT during this period (1:2 ratio) with matched gender, age, and diagnosis. The incidence of OM and overall survival (OS) were compared between the two groups. <b>Results:</b> The secondary allo-HSCT and control groups reported 17 (29.31%) and 16 (13.79%) cases that developed OM (<i>P</i>=0.014), whereas 10 (17.24%) and 7 (6.03%) developed grade ≥3 OM (<i>P</i>=0.019). The median time for OM to occur was 4 days (1-9 days) and 5 days (1-10 days) posttransplantation in the secondary allo-HSCT and control groups, respectively. The multivariate analysis revealed that the use of whole-body radiation therapy as the main pretreatment regimen was an independent risk factor for OM occurrence (<i>P</i>=0.019). Among patients with OM, an age of <55 years is a risk factor for developing grade 3-4 OM (<i>P</i>=0.028). All patients who underwent the secondary allo-HSCT received granulocyte implantation. The median time of granulocyte implantation in 17 patients with OM was 14 days posttransplantation, whereas the median time of granulocyte implantation in patients without OM was 12 days posttransplantation. The difference was not statistically significant (<i>P</i>=0.721). The presence of OM did not affect the occurrence of acute graft-versus-host disease (<i>P</i>=0.938). No statistically significant difference was observed in the 2-year OS rate between patients with and without OM during the secondary allo-HSCT (51.9% <i>vs</i> 50.4%, <i>P</i>=0.943). No statistically significant difference was observed in the 2-year OS rate between patients with OM undergoing the secondary allo-HSCT and those undergoing the primary allo-HSCT (51.9% <i>vs</i> 81.3%, <i>P</i>=0.185) . <b>Conclusions:</b> The proportion of patients with concurrent OM was significantly increased in the secondary allo-HSCT, and the severity was more severe. Whether or not to merge OM does not affect granulocyte implantation, acute graft-versus-host disease incidence, and 2-year OS rate.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"45 12","pages":"1078-1084"},"PeriodicalIF":0.0,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143575785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Acute promyelocytic leukemia peripheral nerve infiltration: a case report].","authors":"Y T Wang, W Chen, K Z Qin, H T Qi, T Z Wang","doi":"10.3760/cma.j.cn121090-20240705-00253","DOIUrl":"https://doi.org/10.3760/cma.j.cn121090-20240705-00253","url":null,"abstract":"","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"45 12","pages":"1142-1143"},"PeriodicalIF":0.0,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Next-generation sequencing-based minimal residual disease detection reveals clonal evolution in pediatric acute B-lymphoblastic leukemia: a case report and literature review].","authors":"J Chang, Y J Jia, H X Wang, B Q Qi, X J Cai, Q Sun, X F Zhu, Z J Xiao, H J Wang","doi":"10.3760/cma.j.cn121090-20240527-00190","DOIUrl":"10.3760/cma.j.cn121090-20240527-00190","url":null,"abstract":"<p><p>Minimal residual disease (MRD), a crucial biomarker for assessing efficacy and predicting recurrence, refers to residual tumor cells remaining in the body of patients with hematological malignancies who achieved complete remission after treatment. This study aimed to conduct a retrospective analysis of the clinical diagnosis, treatment, and MRD monitoring of a pediatric patient with multiple acute B-lymphocytic leukemia relapses, alongside a review of relevant literature. In this case, Ig rearrangement based on next-generation sequencing (NGS) was more accurate in assessing the MRD level, compared with the traditional method of MRD detection, indicating the risk of earlier relapse and guided interventions in time. Additionally, NGS-MRD detected clonal evolution, providing new ideas to further investigate the intrinsic factors of disease development.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"45 12","pages":"1138-1141"},"PeriodicalIF":0.0,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143575743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}